Stay updated on Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page.

Latest updates to the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page
- Check6 days agoChange DetectedThe study record's revision label was updated from v3.6.6 to v3.7.0. This reflects a new version of the page rather than changes to the study content.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedA new revision entry v3.6.6 was added to the study history, and the previous entry v3.6.5 was removed. This is an update to the record's revision metadata on ClinicalTrials.gov rather than substantive content.SummaryDifference0.1%

- Check41 days agoChange DetectedA new revision entry v3.6.5 was added to the study history as the latest revision. The previous v3.6.4 entry was removed from the current change set.SummaryDifference0.1%

- Check63 days agoChange DetectedThe revision label on the page history updated from v3.6.3 to v3.6.4, signaling a software update to the page rendering system.SummaryDifference0.1%

- Check84 days agoChange DetectedA new Revision: v3.6.3 was added to the record history. The previous Revision: v3.6.0 was removed from the history.SummaryDifference0.1%

- Check98 days agoChange DetectedAdded a note that the study is not recruiting participants. The revision tag was updated to v3.6.0, replacing the previous v3.5.5.SummaryDifference0.3%

Stay in the know with updates to Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page.